Physician profile
Daniel Trock
NPI 1639134885
$19,757.57
in general payments reported to CMS, 2019-2025
69 companies · $2,966 in 2025
The $2,966 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,718 · 2020: $1,531 · 2021: $2,979 · 2022: $2,953 · 2023: $3,078 · 2024: $3,534 · 2025: $2,966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,577.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,732.18 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,958.21 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Lilly USA, LLC | $1,870.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $1,739.46 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,247.49 | 2019-2025 | |
| Novo Nordisk INC | $1,114.46 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $923.78 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $580.75 | 2019-2025 | Repatha, Otezla, Otezla |
| Ucb, INC. | $569.09 | 2022-2025 | Rystiggo, Briviact, Nayzilam |
| Otsuka America Pharmaceutical, INC. | $489.78 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $469.20 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $459.75 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $413.38 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $359.41 | 2021-2025 | |
| Tg Therapeutics, INC. | $349.51 | 2023-2025 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Trock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.